English

TANGO THERAPEUTICS, INC.

EDGAR

BCTG Current report (8-K) · filed 2026-10-23

Annual consolidated revenue for 2025: about USD 62.38M, using the latest reported figures. The previous period, 2024, was about USD 42.07M.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

0 USD

2026 Q2 · USD

Exact inputs and evidence

Revenue: 0 USD Source

Operating cash flow

-38.9 million USD

2026 Q2 · USD

Exact inputs and evidence

Operating Cash Flow: -83226000 USD Source
Operating Cash Flow: -44360000 USD Source

Cash and cash equivalents: 346 million USD 2026-06-30 Source
Exact value

345558000 USD
Long-term debt including current maturities: Not available
Shares outstanding: 168 million shares 2026-06-30 Source
Exact value

168380091 shares

Reported share-count change

51.87% · 57.5 million shares

Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.

Exact inputs and evidence

110871249 shares · 2025-06-30· Source
168380091 shares · 2026-06-30· Source

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Revenue

53.8 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Revenue: 53811000 USD · 2025-07-01 – 2025-09-30 Source
Revenue: 62384000 USD · 2025-01-01 – 2025-12-31 Source
Revenue: 62384000 USD · 2025-01-01 – 2025-09-30 Source
Revenue: 0 USD · 2026-01-01 – 2026-03-31 Source
Revenue: 0 USD · 2026-04-01 – 2026-06-30 Source

Net income

-124 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Net income: 15884000 USD · 2025-07-01 – 2025-09-30 Source
Net income: -101594000 USD · 2025-01-01 – 2025-12-31 Source
Net income: -62845000 USD · 2025-01-01 – 2025-09-30 Source
Net income: -45514000 USD · 2026-01-01 – 2026-03-31 Source
Net income: -55341000 USD · 2026-04-01 – 2026-06-30 Source

Operating cash flow

-144 million USD

2025-07-01 – 2026-06-30

Exact inputs and evidence

Operating cash flow: -109168000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -78216000 USD · 2025-01-01 – 2025-06-30 Source
Operating cash flow: -138886000 USD · 2025-01-01 – 2025-12-31 Source
Operating cash flow: -109168000 USD · 2025-01-01 – 2025-09-30 Source
Operating cash flow: -44360000 USD · 2026-01-01 – 2026-03-31 Source
Operating cash flow: -83226000 USD · 2026-01-01 – 2026-06-30 Source
Operating cash flow: -44360000 USD · 2026-01-01 – 2026-03-31 Source

Capital expenditure

1.05 million USD

2025-01-01 – 2025-12-31

Exact inputs and evidence

Capital expenditure: 51000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 675000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 51000 USD · 2025-01-01 – 2025-03-31 Source
Capital expenditure: 826000 USD · 2025-01-01 – 2025-09-30 Source
Capital expenditure: 675000 USD · 2025-01-01 – 2025-06-30 Source
Capital expenditure: 1048000 USD · 2025-01-01 – 2025-12-31 Source
Capital expenditure: 826000 USD · 2025-01-01 – 2025-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2026-10-23.

Financial data available through: 2025-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2025-12-31
Operating income: 7 of 11 periods available· newest 2025-12-31
Net income: 7 of 11 periods available· newest 2025-12-31
Operating cash flow: 7 of 11 periods available· newest 2025-12-31
Capital expenditure: 7 of 11 periods available· newest 2025-12-31
Total assets: 6 of 11 periods available· newest 2025-12-31
Total liabilities: 6 of 11 periods available· newest 2025-12-31
Current assets: 6 of 11 periods available· newest 2025-12-31
Current liabilities: 6 of 11 periods available· newest 2025-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2025-12-31
long term debt: No compatible figures in this window
Shares outstanding: 6 of 11 periods available· newest 2025-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+48.3%

Prior period

USD 42.07 million

2024-01-01 – 2024-12-31
Current period

USD 62.38 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

62384000 − 42069000 = 20315000 USD

42069000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
62384000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · TANGO THERAPEUTICS, INC. · 2025-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Year-over-year change in Revenue: 20315000 USD Concept: fundies:Revenue Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 62384000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#3387584 Filing: 000119312526092518 Input fundies:Revenue: 42069000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#3389213 Filing: 000119312526092518
The citation records this snapshot. The page link may show a newer release later.
Net income
+USD 28.71 million

Prior period

−USD 130.3 million

2024-01-01 – 2024-12-31
Current period

−USD 101.59 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-101594000 − -130302000 = 28708000 USD

-130302000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-101594000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · TANGO THERAPEUTICS, INC. · 2025-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Year-over-year change in Net income: 28708000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -101594000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#3451328 Filing: 000119312526092518 Input fundies:NetIncome: -130302000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#3453189 Filing: 000119312526092518
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−USD 7.39 million

Prior period

−USD 131.5 million

2024-01-01 – 2024-12-31
Current period

−USD 138.89 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

-138886000 − -131501000 = -7385000 USD

-131501000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
-138886000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · TANGO THERAPEUTICS, INC. · 2025-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Year-over-year change in Operating cash flow: -7385000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -138886000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2227154 Filing: 000119312526092518 Input fundies:OperatingCashFlow: -131501000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2228906 Filing: 000119312526092518
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+39%

Prior period

USD 754,000

2024-01-01 – 2024-12-31
Current period

USD 1.05 million

2025-01-01 – 2025-12-31

Exact inputs and evidence

1048000 − 754000 = 294000 USD

754000 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source
1048000 USD · 2025-01-01 – 2025-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · TANGO THERAPEUTICS, INC. · 2025-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Year-over-year change in Capital expenditure: 294000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1048000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2236468 Filing: 000119312526092518 Input fundies:CapitalExpenditure: 754000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2238209 Filing: 000119312526092518
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2025 2025-01-01 – 2025-12-31

Revenue USD 62.38 million 100% of revenue
Operating costs Derived USD 173.67 million 278% of revenue
Operating income −USD 111.29 million −178% of revenue
Tax, interest and other Derived −USD 9.7 million −16% of revenue
Net income −USD 101.59 million −163% of revenue

Cash

Operating cash flow −USD 138.89 million −223% of revenue
Capital expenditure USD 1.05 million 1.7% of revenue
Free cash flow Derived −USD 139.93 million −224% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2020 Operating loss: operating costs were 782% of revenue.
2021 Operating loss: operating costs were 257% of revenue.
2022 Operating loss: operating costs were 547% of revenue.
2023 Operating loss: operating costs were 413% of revenue.
2024 Operating loss: operating costs were 446% of revenue.
2025 Operating loss: operating costs were 278% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2020 2020-01-01 – 2020-12-31	7656000	59856000 Derived	-52200000	-228000 Derived	-51972000	68968000 Derived	Source 2020-01-01 – 2020-12-31: 7656000 USD Inspect Revenue Open source 2020-01-01 – 2020-12-31: -52200000 USD Inspect Operating Income Open source 2020-01-01 – 2020-12-31: -51972000 USD Inspect Net Income Open source 2020-01-01 – 2020-12-31: 70074000 USD Inspect Operating Cash Flow Open source 2020-01-01 – 2020-12-31: 1106000 USD Inspect Capital Expenditure Open source
2021 2021-01-01 – 2021-12-31	37042000	95232000 Derived	-58190000	45000 Derived	-58235000	-61364000 Derived	Source 2021-01-01 – 2021-12-31: 37042000 USD Inspect Revenue Open source 2021-01-01 – 2021-12-31: -58190000 USD Inspect Operating Income Open source 2021-01-01 – 2021-12-31: -58235000 USD Inspect Net Income Open source 2021-01-01 – 2021-12-31: -59527000 USD Inspect Operating Cash Flow Open source 2021-01-01 – 2021-12-31: 1837000 USD Inspect Capital Expenditure Open source
2022 2022-01-01 – 2022-12-31	24860000	135931000 Derived	-111071000	-2895000 Derived	-108176000	-116772000 Derived	Source 2022-01-01 – 2022-12-31: 24860000 USD Inspect Revenue Open source 2022-01-01 – 2022-12-31: -111071000 USD Inspect Operating Income Open source 2022-01-01 – 2022-12-31: -108176000 USD Inspect Net Income Open source 2022-01-01 – 2022-12-31: -109080000 USD Inspect Operating Cash Flow Open source 2022-01-01 – 2022-12-31: 7692000 USD Inspect Capital Expenditure Open source
2023 2023-01-01 – 2023-12-31	36527000	150700000 Derived	-114173000	-12429000 Derived	-101744000	-119508000 Derived	Source 2023-01-01 – 2023-12-31: 36527000 USD Inspect Revenue Open source 2023-01-01 – 2023-12-31: -114173000 USD Inspect Operating Income Open source 2023-01-01 – 2023-12-31: -101744000 USD Inspect Net Income Open source 2023-01-01 – 2023-12-31: -117982000 USD Inspect Operating Cash Flow Open source 2023-01-01 – 2023-12-31: 1526000 USD Inspect Capital Expenditure Open source
2024 2024-01-01 – 2024-12-31	42069000	187664000 Derived	-145595000	-15293000 Derived	-130302000	-132255000 Derived	Source 2024-01-01 – 2024-12-31: 42069000 USD Inspect Revenue Open source 2024-01-01 – 2024-12-31: -145595000 USD Inspect Operating Income Open source 2024-01-01 – 2024-12-31: -130302000 USD Inspect Net Income Open source 2024-01-01 – 2024-12-31: -131501000 USD Inspect Operating Cash Flow Open source 2024-01-01 – 2024-12-31: 754000 USD Inspect Capital Expenditure Open source
2025 2025-01-01 – 2025-12-31	62384000	173673000 Derived	-111289000	-9695000 Derived	-101594000	-139934000 Derived	Source 2025-01-01 – 2025-12-31: 62384000 USD Inspect Revenue Open source 2025-01-01 – 2025-12-31: -111289000 USD Inspect Operating Income Open source 2025-01-01 – 2025-12-31: -101594000 USD Inspect Net Income Open source 2025-01-01 – 2025-12-31: -138886000 USD Inspect Operating Cash Flow Open source 2025-01-01 – 2025-12-31: 1048000 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 62.4M 2025

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Revenue	7656000	Revenue: 7656000 Open source
20212021-12-31	Revenue	37042000	Revenue: 37042000 Open source
20222022-12-31	Revenue	24860000	Revenue: 24860000 Open source
20232023-12-31	Revenue	36527000	Revenue: 36527000 Open source
20242024-12-31	Revenue	42069000	Revenue: 42069000 Open source
20252025-12-31	Revenue	62384000	Revenue: 62384000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

48.3% 2025

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Year over year	No prior comparable period	Revenue: 7656000 Open source
20212021-12-31	Year over year	383.8%	Revenue: 37042000 Open source Revenue: 7656000 Open source
20222022-12-31	Year over year	-32.9%	Revenue: 24860000 Open source Revenue: 37042000 Open source
20232023-12-31	Year over year	46.9%	Revenue: 36527000 Open source Revenue: 24860000 Open source
20242024-12-31	Year over year	15.2%	Revenue: 42069000 Open source Revenue: 36527000 Open source
20252025-12-31	Year over year	48.3%	Revenue: 62384000 Open source Revenue: 42069000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -178.4% 2025

Net margin -162.9% 2025

Free cash flow margin -224.3% 2025

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Operating margin	-681.8%	Operating Income: -52200000 Open source Revenue: 7656000 Open source
20212021-12-31	Operating margin	-157.1%	Operating Income: -58190000 Open source Revenue: 37042000 Open source
20222022-12-31	Operating margin	-446.8%	Operating Income: -111071000 Open source Revenue: 24860000 Open source
20232023-12-31	Operating margin	-312.6%	Operating Income: -114173000 Open source Revenue: 36527000 Open source
20242024-12-31	Operating margin	-346.1%	Operating Income: -145595000 Open source Revenue: 42069000 Open source
20252025-12-31	Operating margin	-178.4%	Operating Income: -111289000 Open source Revenue: 62384000 Open source
20202020-12-31	Net margin	-678.8%	Net Income: -51972000 Open source Revenue: 7656000 Open source
20212021-12-31	Net margin	-157.2%	Net Income: -58235000 Open source Revenue: 37042000 Open source
20222022-12-31	Net margin	-435.1%	Net Income: -108176000 Open source Revenue: 24860000 Open source
20232023-12-31	Net margin	-278.5%	Net Income: -101744000 Open source Revenue: 36527000 Open source
20242024-12-31	Net margin	-309.7%	Net Income: -130302000 Open source Revenue: 42069000 Open source
20252025-12-31	Net margin	-162.9%	Net Income: -101594000 Open source Revenue: 62384000 Open source
20202020-12-31	Free cash flow margin	900.8%	Revenue: 7656000 Open source Operating Cash Flow: 70074000 Open source Capital Expenditure: 1106000 Open source
20212021-12-31	Free cash flow margin	-165.7%	Revenue: 37042000 Open source Operating Cash Flow: -59527000 Open source Capital Expenditure: 1837000 Open source
20222022-12-31	Free cash flow margin	-469.7%	Revenue: 24860000 Open source Operating Cash Flow: -109080000 Open source Capital Expenditure: 7692000 Open source
20232023-12-31	Free cash flow margin	-327.2%	Revenue: 36527000 Open source Operating Cash Flow: -117982000 Open source Capital Expenditure: 1526000 Open source
20242024-12-31	Free cash flow margin	-314.4%	Revenue: 42069000 Open source Operating Cash Flow: -131501000 Open source Capital Expenditure: 754000 Open source
20252025-12-31	Free cash flow margin	-224.3%	Revenue: 62384000 Open source Operating Cash Flow: -138886000 Open source Capital Expenditure: 1048000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD -138.9M 2025

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Operating cash flow	70074000	Operating Cash Flow: 70074000 Open source
20212021-12-31	Operating cash flow	-59527000	Operating Cash Flow: -59527000 Open source
20222022-12-31	Operating cash flow	-109080000	Operating Cash Flow: -109080000 Open source
20232023-12-31	Operating cash flow	-117982000	Operating Cash Flow: -117982000 Open source
20242024-12-31	Operating cash flow	-131501000	Operating Cash Flow: -131501000 Open source
20252025-12-31	Operating cash flow	-138886000	Operating Cash Flow: -138886000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -139.9M 2025

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20202020-12-31	Free cash flow	68968000	Operating Cash Flow: 70074000 Open source Capital Expenditure: 1106000 Open source
20212021-12-31	Free cash flow	-61364000	Operating Cash Flow: -59527000 Open source Capital Expenditure: 1837000 Open source
20222022-12-31	Free cash flow	-116772000	Operating Cash Flow: -109080000 Open source Capital Expenditure: 7692000 Open source
20232023-12-31	Free cash flow	-119508000	Operating Cash Flow: -117982000 Open source Capital Expenditure: 1526000 Open source
20242024-12-31	Free cash flow	-132255000	Operating Cash Flow: -131501000 Open source Capital Expenditure: 754000 Open source
20252025-12-31	Free cash flow	-139934000	Operating Cash Flow: -138886000 Open source Capital Expenditure: 1048000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

13.2% 2025

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Liabilities / assets	81.4%	Total Liabilities: 168652000 Open source Total Assets: 207252000 Open source
20212021-12-31	Liabilities / assets	31.1%	Total Liabilities: 155408000 Open source Total Assets: 500155000 Open source
20222022-12-31	Liabilities / assets	42.8%	Total Liabilities: 186994000 Open source Total Assets: 436470000 Open source
20232023-12-31	Liabilities / assets	37.1%	Total Liabilities: 149459000 Open source Total Assets: 402567000 Open source
20242024-12-31	Liabilities / assets	37%	Total Liabilities: 116975000 Open source Total Assets: 316492000 Open source
20252025-12-31	Liabilities / assets	13.2%	Total Liabilities: 52511000 Open source Total Assets: 398690000 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

16.32× 2025

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20202020-12-31	Current assets / current liabilities	4.73×	Current Assets: 193632000 Open source Current Liabilities: 40917000 Open source
20212021-12-31	Current assets / current liabilities	12.1×	Current Assets: 492338000 Open source Current Liabilities: 40690000 Open source
20222022-12-31	Current assets / current liabilities	6.76×	Current Assets: 375272000 Open source Current Liabilities: 55545000 Open source
20232023-12-31	Current assets / current liabilities	7.54×	Current Assets: 346538000 Open source Current Liabilities: 45938000 Open source
20242024-12-31	Current assets / current liabilities	6.98×	Current Assets: 266343000 Open source Current Liabilities: 38170000 Open source
20252025-12-31	Current assets / current liabilities	16.32×	Current Assets: 353756000 Open source Current Liabilities: 21679000 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2019 2019-01-01 – 2019-12-31	−USD 14.1 million Exact value Exact value: -14095000 USD 2019-01-01 – 2019-12-31: -14095000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TANGO THERAPEUTICS, INC. · 2019-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Net Income: -14095000 USD Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:NetIncome: -14095000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312521269987/d118907ds1.htm#5071622 Filing: 000119312521269987 The citation records this snapshot. The page link may show a newer release later.	−USD 24.8 million Exact value Exact value: -24803000 USD 2019-01-01 – 2019-12-31: -24803000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TANGO THERAPEUTICS, INC. · 2019-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Operating Cash Flow: -24803000 USD Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -24803000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312521269987/d118907ds1.htm#4400910 Filing: 000119312521269987 The citation records this snapshot. The page link may show a newer release later.	USD 1.82 million Exact value Exact value: 1817000 USD 2019-01-01 – 2019-12-31: 1817000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TANGO THERAPEUTICS, INC. · 2019-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Capital Expenditure: 1817000 USD Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1817000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312521269987/d118907ds1.htm#4403602 Filing: 000119312521269987 The citation records this snapshot. The page link may show a newer release later.	−USD 26.62 million Calculation and evidence -24803000 − 1817000 USD Exact free cash flow: -26620000 USD 2019-01-01 – 2019-12-31: -24803000 USD · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1817000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TANGO THERAPEUTICS, INC. · 2019-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Free cash flow: -26620000 USD Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -24803000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312521269987/d118907ds1.htm#4400910 Filing: 000119312521269987 Input fundies:CapitalExpenditure: 1817000 USD (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312521269987/d118907ds1.htm#4403602 Filing: 000119312521269987 The citation records this snapshot. The page link may show a newer release later.
2020 2020-01-01 – 2020-12-31	−USD 51.97 million Exact value Exact value: -51972000 USD 2020-01-01 – 2020-12-31: -51972000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TANGO THERAPEUTICS, INC. · 2020-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Net Income: -51972000 USD Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:NetIncome: -51972000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017022004721/tngx-20211231.htm#4791381 Filing: 000095017022004721 The citation records this snapshot. The page link may show a newer release later.	USD 70.07 million Exact value Exact value: 70074000 USD 2020-01-01 – 2020-12-31: 70074000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TANGO THERAPEUTICS, INC. · 2020-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Operating Cash Flow: 70074000 USD Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 70074000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017022004721/tngx-20211231.htm#3587402 Filing: 000095017022004721 The citation records this snapshot. The page link may show a newer release later.	USD 1.11 million Exact value Exact value: 1106000 USD 2020-01-01 – 2020-12-31: 1106000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TANGO THERAPEUTICS, INC. · 2020-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Capital Expenditure: 1106000 USD Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1106000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017022004721/tngx-20211231.htm#3594466 Filing: 000095017022004721 The citation records this snapshot. The page link may show a newer release later.	USD 68.97 million Calculation and evidence 70074000 − 1106000 USD Exact free cash flow: 68968000 USD 2020-01-01 – 2020-12-31: 70074000 USD · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 1106000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TANGO THERAPEUTICS, INC. · 2020-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Free cash flow: 68968000 USD Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 70074000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017022004721/tngx-20211231.htm#3587402 Filing: 000095017022004721 Input fundies:CapitalExpenditure: 1106000 USD (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017022004721/tngx-20211231.htm#3594466 Filing: 000095017022004721 The citation records this snapshot. The page link may show a newer release later.
2021 2021-01-01 – 2021-12-31	−USD 58.24 million Exact value Exact value: -58235000 USD 2021-01-01 – 2021-12-31: -58235000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TANGO THERAPEUTICS, INC. · 2021-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Net Income: -58235000 USD Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:NetIncome: -58235000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017023009854/tngx-20221231.htm#3738195 Filing: 000095017023009854 The citation records this snapshot. The page link may show a newer release later.	−USD 59.53 million Exact value Exact value: -59527000 USD 2021-01-01 – 2021-12-31: -59527000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TANGO THERAPEUTICS, INC. · 2021-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Operating Cash Flow: -59527000 USD Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -59527000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017023009854/tngx-20221231.htm#2405737 Filing: 000095017023009854 The citation records this snapshot. The page link may show a newer release later.	USD 1.84 million Exact value Exact value: 1837000 USD 2021-01-01 – 2021-12-31: 1837000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TANGO THERAPEUTICS, INC. · 2021-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Capital Expenditure: 1837000 USD Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1837000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017023009854/tngx-20221231.htm#2413677 Filing: 000095017023009854 The citation records this snapshot. The page link may show a newer release later.	−USD 61.36 million Calculation and evidence -59527000 − 1837000 USD Exact free cash flow: -61364000 USD 2021-01-01 – 2021-12-31: -59527000 USD · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1837000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TANGO THERAPEUTICS, INC. · 2021-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Free cash flow: -61364000 USD Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -59527000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017023009854/tngx-20221231.htm#2405737 Filing: 000095017023009854 Input fundies:CapitalExpenditure: 1837000 USD (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017023009854/tngx-20221231.htm#2413677 Filing: 000095017023009854 The citation records this snapshot. The page link may show a newer release later.
2022 2022-01-01 – 2022-12-31	−USD 108.18 million Exact value Exact value: -108176000 USD 2022-01-01 – 2022-12-31: -108176000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TANGO THERAPEUTICS, INC. · 2022-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Net Income: -108176000 USD Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:NetIncome: -108176000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017025028353/tngx-20241231.htm#3193811 Filing: 000095017025028353 The citation records this snapshot. The page link may show a newer release later.	−USD 109.08 million Exact value Exact value: -109080000 USD 2022-01-01 – 2022-12-31: -109080000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TANGO THERAPEUTICS, INC. · 2022-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Operating Cash Flow: -109080000 USD Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -109080000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017025028353/tngx-20241231.htm#2092782 Filing: 000095017025028353 The citation records this snapshot. The page link may show a newer release later.	USD 7.69 million Exact value Exact value: 7692000 USD 2022-01-01 – 2022-12-31: 7692000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TANGO THERAPEUTICS, INC. · 2022-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Capital Expenditure: 7692000 USD Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 7692000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017025028353/tngx-20241231.htm#2100876 Filing: 000095017025028353 The citation records this snapshot. The page link may show a newer release later.	−USD 116.77 million Calculation and evidence -109080000 − 7692000 USD Exact free cash flow: -116772000 USD 2022-01-01 – 2022-12-31: -109080000 USD · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 7692000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TANGO THERAPEUTICS, INC. · 2022-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Free cash flow: -116772000 USD Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -109080000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017025028353/tngx-20241231.htm#2092782 Filing: 000095017025028353 Input fundies:CapitalExpenditure: 7692000 USD (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000095017025028353/tngx-20241231.htm#2100876 Filing: 000095017025028353 The citation records this snapshot. The page link may show a newer release later.
2023 2023-01-01 – 2023-12-31	−USD 101.74 million Exact value Exact value: -101744000 USD 2023-01-01 – 2023-12-31: -101744000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TANGO THERAPEUTICS, INC. · 2023-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Net Income: -101744000 USD Concept: fundies:NetIncome Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3ANetIncome&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:NetIncome: -101744000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#3455050 Filing: 000119312526092518 The citation records this snapshot. The page link may show a newer release later.	−USD 117.98 million Exact value Exact value: -117982000 USD 2023-01-01 – 2023-12-31: -117982000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TANGO THERAPEUTICS, INC. · 2023-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Operating Cash Flow: -117982000 USD Concept: fundies:OperatingCashFlow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3AOperatingCashFlow&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -117982000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2230658 Filing: 000119312526092518 The citation records this snapshot. The page link may show a newer release later.	USD 1.53 million Exact value Exact value: 1526000 USD 2023-01-01 – 2023-12-31: 1526000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TANGO THERAPEUTICS, INC. · 2023-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Capital Expenditure: 1526000 USD Concept: fundies:CapitalExpenditure Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3ACapitalExpenditure&period=2023-12-31&surface=latest&period_type=duration&start=2023-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1526000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2239948 Filing: 000119312526092518 The citation records this snapshot. The page link may show a newer release later.	−USD 119.51 million Calculation and evidence -117982000 − 1526000 USD Exact free cash flow: -119508000 USD 2023-01-01 – 2023-12-31: -117982000 USD · Inspect Operating Cash Flow · Source 2023-01-01 – 2023-12-31: 1526000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TANGO THERAPEUTICS, INC. · 2023-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Free cash flow: -119508000 USD Concept: free-cash-flow Period: 2023-01-01 to 2023-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -117982000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2230658 Filing: 000119312526092518 Input fundies:CapitalExpenditure: 1526000 USD (2023-01-01 to 2023-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2239948 Filing: 000119312526092518 The citation records this snapshot. The page link may show a newer release later.
2024 2024-01-01 – 2024-12-31	−USD 130.3 million Exact value Exact value: -130302000 USD 2024-01-01 – 2024-12-31: -130302000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TANGO THERAPEUTICS, INC. · 2024-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Net Income: -130302000 USD Concept: fundies:NetIncome Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3ANetIncome&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:NetIncome: -130302000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#3453189 Filing: 000119312526092518 The citation records this snapshot. The page link may show a newer release later.	−USD 131.5 million Exact value Exact value: -131501000 USD 2024-01-01 – 2024-12-31: -131501000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TANGO THERAPEUTICS, INC. · 2024-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Operating Cash Flow: -131501000 USD Concept: fundies:OperatingCashFlow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3AOperatingCashFlow&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -131501000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2228906 Filing: 000119312526092518 The citation records this snapshot. The page link may show a newer release later.	USD 754,000 Exact value Exact value: 754000 USD 2024-01-01 – 2024-12-31: 754000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TANGO THERAPEUTICS, INC. · 2024-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Capital Expenditure: 754000 USD Concept: fundies:CapitalExpenditure Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3ACapitalExpenditure&period=2024-12-31&surface=latest&period_type=duration&start=2024-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 754000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2238209 Filing: 000119312526092518 The citation records this snapshot. The page link may show a newer release later.	−USD 132.26 million Calculation and evidence -131501000 − 754000 USD Exact free cash flow: -132255000 USD 2024-01-01 – 2024-12-31: -131501000 USD · Inspect Operating Cash Flow · Source 2024-01-01 – 2024-12-31: 754000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TANGO THERAPEUTICS, INC. · 2024-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Free cash flow: -132255000 USD Concept: free-cash-flow Period: 2024-01-01 to 2024-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -131501000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2228906 Filing: 000119312526092518 Input fundies:CapitalExpenditure: 754000 USD (2024-01-01 to 2024-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2238209 Filing: 000119312526092518 The citation records this snapshot. The page link may show a newer release later.
2025 2025-01-01 – 2025-12-31	−USD 101.59 million Exact value Exact value: -101594000 USD 2025-01-01 – 2025-12-31: -101594000 USD Inspect Net Income Open source Share or cite Citation for Net Income · TANGO THERAPEUTICS, INC. · 2025-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Net Income: -101594000 USD Concept: fundies:NetIncome Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3ANetIncome&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:NetIncome: -101594000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#3451328 Filing: 000119312526092518 The citation records this snapshot. The page link may show a newer release later.	−USD 138.89 million Exact value Exact value: -138886000 USD 2025-01-01 – 2025-12-31: -138886000 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · TANGO THERAPEUTICS, INC. · 2025-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Operating Cash Flow: -138886000 USD Concept: fundies:OperatingCashFlow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3AOperatingCashFlow&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -138886000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2227154 Filing: 000119312526092518 The citation records this snapshot. The page link may show a newer release later.	USD 1.05 million Exact value Exact value: 1048000 USD 2025-01-01 – 2025-12-31: 1048000 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · TANGO THERAPEUTICS, INC. · 2025-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Capital Expenditure: 1048000 USD Concept: fundies:CapitalExpenditure Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133/explain?concept=fundies%3ACapitalExpenditure&period=2025-12-31&surface=latest&period_type=duration&start=2025-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1048000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2236468 Filing: 000119312526092518 The citation records this snapshot. The page link may show a newer release later.	−USD 139.93 million Calculation and evidence -138886000 − 1048000 USD Exact free cash flow: -139934000 USD 2025-01-01 – 2025-12-31: -138886000 USD · Inspect Operating Cash Flow · Source 2025-01-01 – 2025-12-31: 1048000 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · TANGO THERAPEUTICS, INC. · 2025-12-31 TANGO THERAPEUTICS, INC. (edgar:1819133) Free cash flow: -139934000 USD Concept: free-cash-flow Period: 2025-01-01 to 2025-12-31 Values: Latest reported Published: 2026-11-02T15:08:24Z Snapshot: 9ee354ae86f58541a4f0ad1cc9596b0a0f8c551e5785dc7f3dc870e26a79300b Dimensions: Consolidated View: https://fundies.io/companies/edgar/1819133?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -138886000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2227154 Filing: 000119312526092518 Input fundies:CapitalExpenditure: 1048000 USD (2025-01-01 to 2025-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1819133/000119312526092518/tngx-20251231.htm#2236468 Filing: 000119312526092518 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

37 filings · 1,718 latest values · 1,718 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001819133, 1819133, BCTG, TNGX, edgar:1819133

Also known as BCTG Acquisition Corp., TANGO THERAPEUTICS, INC., Tango Therapeutics, Inc.

TANGO THERAPEUTICS, INC.

Latest quarter

Revenue

Operating cash flow

Reported share-count change

Trailing twelve months

Revenue

Net income

Operating cash flow

Capital expenditure

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2025 2025-01-01 – 2025-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation